CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?

Overview Forecast RevenueFinancials Chart

CRISPR Therapeutics Ownership Summary

CRISPR Therapeutics is owned by 82.58% institutional investors, 1.61% insiders, and 15.80% retail investors. Ark investment management is the largest institutional shareholder, holding 11.24% of CRSP shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 7.97% of its assets in CRISPR Therapeutics shares.

CRSP Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	CRISPR Therapeutics	82.58%	1.61%	15.80%
Sector	Healthcare Stocks	42.50%	10.81%	46.69%
Industry	Biotech Stocks	45.24%	10.75%	44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ark investment management	9.79M	11.24%	$634.29B
Blackrock funding, inc. /de	7.05M	8.10%	$456.92M
Capital investors	5.65M	6.49%	$366.13M
Orbis allan gray	4.98M	5.72%	$322.89M
State street	4.01M	4.60%	$259.71M
T. rowe price investment management	3.28M	3.77%	$212.75M
Blackrock	2.78M	3.40%	$150.03M
Vanguard group	2.36M	2.72%	$153.25M
Ubs group	2.34M	2.69%	$151.59M
Nikko asset management americas	2.16M	2.48%	$140.18M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Sr one capital management, lp	2.04M	19.11%	$132.13M
Pathway capital management, lp	50.05K	15.95%	$3.24M
Spear rsc	165.00K	6.29%	$8.91M
Versant venture management	148.83K	4.54%	$9.65M
Ecor1 capital	1.39M	4.32%	$90.04M
Ark investment management	9.79M	3.78%	$634.29B
Nea management company	1.06M	3.76%	$68.61M
Green alpha advisors	55.01K	3.44%	$3.57M
Contrarius investment management	685.72K	2.32%	$37.04M
O'neil global advisors	168.72K	2.01%	$10.93M

Top Buyers

Holder	Shares	% Assets	Change
Orbis allan gray	4.98M	1.39%	2.22M
Sr one capital management, lp	2.04M	19.11%	989.81K
Blackrock funding, inc. /de	7.05M	0.01%	983.79K
Morgan stanley	1.40M	0.01%	886.48K
State street	4.01M	0.01%	736.64K

Top Sellers

Holder	Shares	% Assets	Change
Ubs asset management americas	-	-	-964.69K
Two sigma advisers, lp	572.97K	0.07%	-771.73K
National bank of canada /fi/	9.82K	0.00%	-725.78K
Baker bros. advisors lp	-	-	-654.10K
Bellevue group	-	-	-610.00K

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	443.54K	0.00%	443.54K	$17.46M
O'neil global advisors	168.72K	2.01%	168.72K	$10.93M
Pathway capital management, lp	50.05K	15.95%	50.05K	$3.24M
Wellington management group llp	36.49K	0.00%	36.49K	$2.36M
Voloridge investment management	32.39K	0.01%	32.39K	$2.10M

Sold Out

Holder	Change
Impact partnership wealth	-1.00
Activest wealth management	-1.00
Carolina wealth advisors	-1.00
Frazier financial advisors	-2.00
Transce3nd	-2.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2025	461	-2.12%	71,905,056	-0.80%	82	1.19%	220	-6.78%	117	15.84%
Jun 30, 2025	457	9.33%	72,312,350	12.69%	83	1.49%	228	31.03%	101	-2.88%
Mar 31, 2025	16	-96.30%	3,317,986	-94.86%	3	0.07%	8	-95.58%	3	-97.52%
Dec 31, 2024	420	-5.83%	64,513,268	8.48%	76	1.57%	174	-	118	-10.61%
Sep 30, 2024	437	-9.15%	59,424,788	-0.24%	69	1.31%	167	-19.71%	131	1.55%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
ARK Disruptive Innovation Full Composite	7.04M	7.97%	-136.93K
ARK Innovation ETF	6.60M	7.25%	25.07K
Capital Group New Perspective Comp	2.15M	2.49%	-406.93K
American Funds New Perspective A	2.15M	2.49%	-406.93K
ARK Genomic Revolution	2.06M	2.33%	-35.46K
iShares Russell 2000 ETF	2.00M	2.20%	-
ARK Genomic Revolution ETF	1.84M	2.03%	-6.57K
American Funds SMALLCAP World A	1.65M	1.91%	-
T. Rowe Price US Mid-Cap Growth Equity	1.49M	1.73%	-1.60K
SPDR® S&P Biotech ETF	1.40M	1.53%	3.11K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 17, 2025	Kulkarni Samarth	Chief Executive Officer	Sell	$3.46M
Oct 14, 2025	Kulkarni Samarth	Chief Executive Officer	Sell	$282.52K
Oct 14, 2025	KASINGER JAMES R.	General Counsel and Secretary	Sell	$71.66K
Aug 18, 2025	Kulkarni Samarth	Chief Executive Officer	Sell	$760.66K
Aug 06, 2025	Treco Douglas A	-	Buy	$1.14M

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	2
2025 Q3	4	1
2025 Q2	-	1
2025 Q1	1	17
2024 Q4	-	5

CRSP Ownership FAQ

Who Owns CRISPR Therapeutics?

CRISPR Therapeutics shareholders are primarily institutional investors at 82.58%, followed by 1.61% insiders and 15.81% retail investors. The average institutional ownership in CRISPR Therapeutics's industry, Biotech Stocks , is 45.24%, which CRISPR Therapeutics exceeds.

Who owns the most shares of CRISPR Therapeutics?

CRISPR Therapeutics’s largest shareholders are Ark investment management (9.79M shares, 11.24%), Blackrock funding, inc. /de (7.05M shares, 8.10%), and Capital investors (5.65M shares, 6.49%). Together, they hold 25.83% of CRISPR Therapeutics’s total shares outstanding.

Does Blackrock own CRISPR Therapeutics?

Yes, BlackRock owns 3.40% of CRISPR Therapeutics, totaling 2.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 150.03M$. In the last quarter, BlackRock increased its holdings by 231.42K shares, a 9.09% change.

Who is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested?

Sr one capital management, lp is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.11% of its assets in 2.04M CRISPR Therapeutics shares, valued at 132.13M$.

Who is the top mutual fund holder of CRISPR Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of CRISPR Therapeutics shares, with 7.97% of its total shares outstanding invested in 7.04M CRISPR Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools